Index

a

acMAL 341, 345
active pharmaceutical ingredients (API) 284, 491
Adam–Gibbs (AG) approach 35, 39, 318
agarose gels 252
amorphization 60, 76
amorphous chiral molecules 138
amorphous drugs
– crystallisationbelow T_g 413
– stability below T_g 41, 414
amorphous forms, patentability 500, 501
– clarity problems in claims 501
– inventive step 506, 510
– novelty 504, 510
– sufficient disclosure 503, 510
amorphous glucose, thermal and non-thermal routes 376
amorphous indomethacin 37
– dielectric susceptibility 42
– DSC heating scans 43
amorphous liquid/glassy material structure 12, 14
amorphous maltitol, dielectric response 47
amorphous mixtures, physical stability, amorphous drugs 22
amorphous polymers 230
amorphous pharmaceutical systems 316
amorphous phase 205
amorphous solid, 2 *see also* disordered solid
dispersion technologies 22
amorphous vs. crystalline itraconazole, dissolution rate 61
Angell's framework 38, 217
anisotropic molecules, point defects 88
anti-Stokes shift 363
antiparallel organization of dipoles 349
API, isomeric structures 183
apparent solubility 23
architectures, polymers 202
aspirin, molecular structure and conformational energy landscape 170
atomic force microscopy
– basics 119
– characterization of defects 121
atomistic simulations, RDX 99
atropisomerism 161
– atropisomers, molecular interconversion 174
– description 172
– iodinated contrast media
– – hindered rotation 175
– – iopamidol and iomeprol 175, 177
– – isomeric conformations 175, 176
atropo-enantiomerism, *see* bis-tetralone
Avrami plot 330
Avrami-Avramov plot 331
Avrami-like function 373

b

β (JG)-relaxation 46, 343
– acMAL 340, 345
– CEL stability 343
– density functional theory 343
– Gordon-Taylor (GT) equation 339
– HPMC 339
– PVP 339
β of Johari–Goldstein type (β_{JG}) 46, 216
β-lactoglobulin (β-Lg) gels, storage shear moduli 255
β-uridinetautomers, dipole moment 193
Böhmer correlation 320
BCS class II drug subdivisions 59

Disordered Pharmaceutical Materials, First Edition. Edited by Marc Descamps.

biodegradation, polymers 259
biopharmaceutical classification system (BCS) 57, 58
bis-tetralone 155
bisvinylsulfonemethyl (BVSM) crosslinker 265
block copolymers 233
BMS-488043 dose, exposure ratios 62, 63
Boltzmann distribution 164
Bose–Einstein factor 364
Boson peak 399
Bragg-Brentano geometry 290
branched polymers 202
broadband dielectric spectroscopy (BDS) 327
– advantage 187
– condensed materials
– – α-relaxation 190
– – γ-relaxation character 190
– – melting–quenching–annealing steps 188
– – glibenclamide drug 189
– – organic compound, equilibrium states 188
– – proton hopping 188
– – proton transfer reaction 187
– – ring–chain tautomerism, carbohydrates 189
– description 301
bulk defects 493
Burgers vector 89
screw dislocation 91

C

caffeine, high temperature hexagonal phase
– crystalline 8
disordered 9
caffeine, form II
– polymorphic transformations 381, 382
– structural description 378
calorimetric glass transition 30
carbohydrates 170
carvedilol phosphate hemihydrate 146
carvone system 144, 145
CEL stability 343
celecoxib (CEL) 336, 339
chain molecules, conformational topology and crystallization 162
charge-coupled device (CCD) 364
chemical etching
– basics 123
– characterization 123
– defects, pharmaceutical crystals 124
chemical shift 429
chiral molecules 135
chirality 138
cinnamic acid crystals
– structure types 94
– photochemical reactivity 94
cis-π-camphanic acid 143
clarity, claims 492
– disordered crystals 7, 493
classical nucleation theory 19, 74
clopidogrel hydrogeno-sulfate 146
co-crystals
– clarity problems in claims 497
– formation 60
– inventive step 499
– novelty 498
– sufficient disclosure 498
Cole-Cole (CC) function 308
Cole-Davidson (CD) approaches 315
Cole-Davidson (CD) function 309
conformational conversion, energy landscape 164
conformational disorder 162
conformational polymorphism 162, 165
– computational approach 166
– crystal structure prediction 166
– definition 165
– flexibility and crystallization 167
– flexible molecule, solution crystallization 167
– physical organic approach 166
– prediction studies 169
contact time 432
conventional film casting 482
cooperatively rearranging region (CRR) 318
copolymers 202, 232
– organised amorphous structure 212
coupling model (CM) 323
Crankshaft-type rotations 216
cross polarization (CP) 432
crosslinked polymers 250
cryogel method, polyester scaffold preparation 271
cryomilling 469
crystal defects, *see also* crystal imperfections
– complementarity of techniques 126
– densities within crystals 125
– nature and abundance 103
– surfaces 119
– techniques 104
– TEM, *see* transmission electron microscopy
– types 103
– within crystals, characterization techniques 104

crystal engineering 346
crystal formation mechanism, solution aggregates 179
crystal imperfections 7, 494
– first kind
– – description 7
– – ice disorder 9, 10
– – one-dimensional monoatomic model 8
– – rotationally disordered crystals 8
– – substitutional disorder 10
– – thermal agitation 7
– line imperfections 89
– pharmaceutical systems 99
– planar imperfections 91, 92
– point defects 87
– second kind 11, 12
crystal lattice, symmetry operator restrictions 136
crystal size effect 5
crystalline lamella 207
crystalline solids 2
– description 2
– elastic behaviour 2
crystalline solution 11
crystalline structures, polymers 206
crystalline-crystalline polymorphic transformation 470
crystallinity quantification 410
crystallisation 16
– amorphous drug above T_g 410
– amorphous drug below T_g 413
– glassy state 335
– ground powder 371
– and structural relaxation 333
– thermodynamic driving force 16
curves 18, 19
9-cyanoanthracene
– photodimerisation 96
– solid-state photochemical reactions 95
– stacking faults 95
L-cysteine 122

d

Debye relaxation 303, 405
Debye theory 399
Debye–Scherrer geometry 290
Debye–Waller factor 8
degradable hydrogels 259
density functional theory (DFT) calculations 343
desolvation process, paracetamol 96
developability classification system (DCS) 59
dextran hydroxyethyl methacrylate (dex-HEMA) hydrogel 259
diacetylenes 95
1,8-dichloro-10-methylanthracene crystals 97
dielectric permittivity 302
dielectric relaxation principles and models, Debye relaxation 303
dielectric response
– disordered materials 397
– and molecular mobility, partially ordered pharmaceutical systems
– – antiparallel organization of dipoles 349
– – crystal engineering 346
– – liquid-crystalline phases 350
– – plastic crystal 347
– – rotator phase 347
dielectric spectra, relaxation processes identification 312
dielectric spectroscopy 218
– essence 301
dielectric susceptibility, amorphous indomethacin 42
different spectroscopic techniques 362
differential scanning calorimetry (DSC) 362, 502
dipolar coupling 429
diprophylline 143, 144
direct classical least squares (DCLS) 370
dislocation, 89 *see also* line imperfections
– dynamics simulations 99
– line 90
disordered biological and pharmaceutical systems
– crystallinity quantification,410
– crystallisation
– – amorphous drug above 410
– – amorphous drug below 413
– – amorphous drug below stability 414
– – multi component disordered pharmaceutical systems 416
disordered crystals 7, 493
– carity, claims 493
– inventive step 496
– novelty 495
– patentability 493
– sufficient disclosure 494
– terahertz studies 400
disordered solids, pharmaceutical formulations 1
dissolution rate 58
2,5-distyrylpyrazine 95
divinyl monomers 95
drug concentration time profile 63

drug crystallization 73
drug supersaturation, *see also* drug-polymer interactions
– cellulose derived polymers 68
– drug–polymer hydrophobic interactions 69
– formulation variables 74
– hydroxypropylmethylcellulose acetate succinate 68
– polymer concentration 71
– polymer structure 68
drug–polymer interactions
– Flory–Huggins theory 71
– ionic interactions 71
– indomethacin solution 72
– solid dispersions 70
dry powder coating 474
dynamic disorder 430
dynamic glass transition 217

e

edge dislocations 89, 91
– RDX and PETN 99
Einstein-Stoke-Debye relation 405
elastic properties, cryogel films 270
electrospinning and spin coating 483
electrospraying 275, 483
electrostatic potentials
– glibemclamide 186
– HDp44mT compound 186
enantiomeric excess 136
enantiomers
– conglomerates 154
– degrees of disorder among crystallized enantiomers 140, 141
– diprophylline 143, 144
– disorders not affecting stereogenic centers 140
– fast racemizable 137
– features 135
– limonene 138
– multi-epitaxy 154
– non racemizable 137, 141
– solvent role 145
– static/dynamic disorder 139
energy landscape topology 49
– fragility 49, 50
– polyamorphism 50
entropic elasticity, polymer networks 250
epitaxy 136
equal area rule 44
erythromycin 186
etching surface, *see* surface etching
5-ethyl-5methylhydantoin antipodes 136
Eudragit E PO 231
excipient gain factor 76
experiment 205
extended Adam-Gibbs model 339

f

far-infrared spectroscopy 395
fast racemizable enantiomers 137
fast secondary relaxation and caged dynamics 398
felodipine solid dispersions 74
fiber based scaffolds, electrospinning 275
fictive temperature of glasses 43
film coating 482
Flack parameter 155
Flory-Stockmayer gel point 261
Flory-Stockmayer theory 261
Flory–Huggins parameter 223
Flory–Huggins theory 71
Fourier transform calculation 288
Fourier transform Raman spectra (FT-Raman) 364
– measurements 502
fragility 320
– concept 319
– pharmaceutical glass formers 32, 34, 37, 321
free enthalpy 15
free induction decay (FID) 429
freeze drying 481
D-fructose
– γ-process 190
– mutarotation process 195
– structure relaxation times 189

g

gelatin gels 252, 254, 264
gelatin hydrogel structure 266
gelatin hydrogels 265
gels 242
– chemical gels 245
– definition 244
– formation 139
– gelatin gels 254, 264
– gelatin hydrogels 265
– globular protein gels 254
– hybrid gels 248
– hydrogels, *see* hydrogels
– physical gels 245
– point 264
– poloxamer gels 266
– sol-gel transition 261
Gibbs Duhem equation 65
Gibbs–Scott phase rule 137

glass–rubber transition behaviour 213
glass formers, disorder
– aging and variability 41
– dynamics and thermodynamics 39
– fictive temperature 43
– glass transition 32
– Kauzmann paradox 33
– non-Arrhenius temperature dependence 36
– non exponential relaxations and dynamic heterogeneity 40
– nonlinearity 44
– secondary relaxations 46
– three nons of glass formers 35
glass materials, amorphous forms 2, 508
glass transition of blends 221
glass transition temperature 205
– definition 3
glass-melting 24
glassy state, crystallization 16, 335
glibemclamide
– electrostatic potentials 186
– relaxation times and static permittivity 191
– selected kinetic curves 194
glibenclamide drug
– dielectric loss spectra 191
– incubation time 194
– structure relaxation times 189
globular protein gels 254
Gordon-Taylor (GT) equation 339
Gordon–Taylor law 138
grain boundaries 91
graphite, stacking faults 92

h

Havriliak and Negami (HN function) 309
Havriliak–Negami (HN) approach 315
HDp44mT compound, electrostatic potentials 186
heterogeneous scenario 323
hexahelicene, molecular conformation 173
high frequency spectrum, raman spectra 369
high power decoupling (HPD) 431
high resolution electron microscopy (HREM) 105
homogeneous scenario 323
hot melt extrusion (HME) and injection molding 474
HPMC 231
hybrid gels 248
hydrochlorothiazide (HCT) 296
hydrogels
– containing sliding crosslinks 248
– description 241
– double-network hydrogels 247
– interpenetrating polymer networks 247
– thermoreversible hydrogels 246
hydrogen-bonded liquids and solutions 404
hydrophobic substituents, polymers 68
hydroxypropyl methylcellulose (HPMC) 339
hydroxypropylmethylcellulose acetate succinate (HPMCAS) 68

i

ibuprofen 374
immiscible polymer blend formulation 70
imperfect crystals 7, *see also* alsocrystalline imperfections
impurity molecules 88
indomethacin (IMC) 371, 470
– amorphous 29, 37, 42
– amorphous state 383
– dissolution behavior 64
– experimental kinetic solubility profile 74
– and poly(vinyl pyrrolidone) blend 222
– solid dispersions 71, 72
– solubility profiles 23
injection molding 477
inorganic glasses 403
interatomic distance 286
intercrystalline links 207
interfacial free enthalpy 20, 21
internal interactions 429
interpenetrating polymer networks (IPNs) 247
in vitro dissolution tests 75
iodinated contrast media (ICM)
– atropisomerism
– – hindered rotation 175
– – iopamidol and iomeprol 175, 177
– – isomeric conformations 175, 176
iopamidol and iomeprol 175, 177
iopanoic acid polymorphs, dissolution rate 60
irradiation process 87
Isobaric fragility 318
isotactic polypropylene, ternary helical conformations 163
isothermal crystallization 329
itraconazole solid dispersions 71, 72, 75

j

Johari-Goldstein (JG) relaxation 314, 323

k

Kauzmann paradox 33
Kauzmann temperature 325
KinetiSol dispersing 477, 478
Kohlrausch-Williams-Watts (KWW) function 308, 311

l

landscape, *see* energy landscape
Laser scattering tomography 125
Lattice vacancy 85
Lauritzen–Hoffman theory 209
leaching techniques, scaffolds 275
limonene 138
line defects 493
line imperfections
– Burgers vector 89
– description 89
– explosive organic systems 99
linear polymers 202
– conformations of chains 203
– semi-crystalline polymers 225
– stereoregularity and configurations 202
liquid and glassy states
– physical stability, drugs 16
– – BDS, supercooled liquid 327
– – vs. cold crystallization 327
– – prediction 324
liquid form 2
liquid-crystalline phases 350
lovirdie supersaturation 76
low-frequency spectrum (LFRS) 366
lyophilisation, *see* freeze drying

m

macrolideantibiotic 186
magic angle spinning (MAS) 431
maltitol 47,48
maribavir 154
masterplot 339
matrix controlled polymerisation 94
melt-electrospinning 477, 478
melt granulation 472
melt-quenching 471
membrane permeability 57
mesh size physical gels 258
meta-toluidine, XRD patterns 14
micro-Raman spectroscopy 382
microcalorimetry 267
microfibrils 208
milling 468
mixing free energy of blends 223
mobilities, polymers 215
mobility islands 323
molecular crystals
periodic property 4
– X-ray powder diagrams 6
molecular mobility
– and dielectric response, partially ordered pharmaceutical systems
– – antiparallel organization of dipoles 349
– – crystal engineering 346
– – liquid-crystalline phases 350
– – plastic crystal 347
– – rotator phase 347
– glassy state 322
– supercooled liquids 317
monomer structures 232
multi component disordered pharmaceutical systems 416
multiamorphicity 50
multivariate analysis (MVA) 370, 382
mutarotation, *see* ring–chain tautomerism

n

nanocomposite hydrogels 249
nanocrystals, patentability clarity problems 509
nanocrystalline itraconazole formulation 62
nematic mesophase formation 352
networks, polymers 202
NH-tautomerism 185
nifedipine, defects 127
non crystalline solids 2
non racemizable enantiomers 137, 141
non-Arrhenius temperature dependence, viscosity and relaxation times 36
non-Debye relaxation models 307
non-equilibrium point defects 87
non-isothermal crystallization 328
normal mode, molecular origin 314
nucleation 17

o

octaacetylmaltose (acMAL) 339
optical microscopy 118
on-line Raman spectroscopy 383
oral drug absorption barriers 57
organic crystals, point defects 88
organic glass-forming liquids 404
– hydrogen-bonded liquids and solutions 404
– supercooled liquids and glasses 407
organic-inorganic IPN 249
orthoterphenyl (OTP) 367

p
pair distribution function (PDF) 13, 502
– applications 292
– – hydrochlorothiazide 296
– – rac-modafinil, polymorphs of 294
– description 284
– interatomic distance 286
– measurement 288
– modelling 290
– *G*(r) yields 285
paracetamol crystals, dislocation dynamics simulations 99
patent applicants 492
patent practitioners 491
patentability
– amorphous forms 500, 501
– – clarity problems in claims 501
– – inventive step 506, 510
– – novelty 504, 510
– – sufficient disclosure 503, 510
– co-crystals 496
– – clarity problems in claims 497
– – inventive step 499
– – novelty 498
– – sufficient disclosure 498
– disordered crystals, *see* disordered crystals, patentability
– nanocrystals 509
– – clarity problems 509
Pauling ice rules 10
PDF, *see* pair distribution function (PDF)
percolation model 262
perfect crystals
– description 2, 3
– periodic property 3
– translational invariance 3
– X-ray diffraction experiment 3, 4
pharmaceutical compositions, amorphous forms 508
pharmaceutical polymers
– architectures, polymers 202
– crystalline structures, polymers 206
– description 201
– dynamic disorders 213
– – glass–rubber transition behaviour 213
– mobilities, polymers 215
– physical behaviour 224
– – amorphous polymers 230
– polymer and small molecules blends 221
– – glass transition of blends 221
– – mixing free energy of blends 223
– – solubility limit, small molecules in polymers 223
– structural states and phases transitions 205
– – amorphous phase 205
– synthetic and natural 225, 226
pharmaceutical processing
– film coating 482
– freeze drying 481
– milling 468
– solvent evaporation-based processing techniques, spray drying 478
pharmaceutical solid formulations development 361
phase separation 26, 246
phase transformations, polymer solutions 269
phase-change materials (PCMs) 402
physical ageing 205
physical gelation 243
physical gels
– conformational changes of polymer chains 245
– denaturation of globular proteins 245
– elasticity 251
– hydrophobic effect 246
– phase separation 246
– swelling 258
– synergy 246
piroxicam 471
– enhanced dissolution 70
planar imperfections 91
plastic crystal, 347 *see also* rotationally disordered crystals
plastic deformation 87
PLGA-nanohydroxyapatite composite scaffolds 273
pluronics® 267
point defects 87, 493
– explosive organic systems 99
Poley absorption 394
poloxamer gels 233, 266
poly(dimethylsiloxane), end-linking reaction 263
poly(L-lactic acid) (PPLA) 218
poly(*N*-isopropylacrylamide) (poly-NIPAM) 246
polyamorphic situations analysis 370
polyamorphism 50
polyelectrolyte gel 256, 257
polyester scaffold preparation, cryogel method 271
polyethylene chain, parameters and topological changes 162
polymer 402
– hydrophobicity 69
polymer, molecular properties 68, 69

polymer networks
– biodegradation and swelling 259
– elasticity, physical gels 251
– entropic elasticity 250
– network swelling 256
polymeric gels 244
polyols study 409
polypeptides 202
polysaccharides 202
polytypism 92
polyvinylpyrrolidone (PVP) 339
pore size distribution 269
porogens 275
porous matrice preparation 275
potential energy hypersurface 33
precipitation inhibition, drugs 69
preferential enrichment
– crystalline nature of compounds 150
– discovery 149
– mechanism 152
– principle and feature 150
– racemic compound crystals 152
– requirements 152
primary (α-) and secondary (β-) relaxations 37, 47, 397, 398
principal component analysis (PCA) 370
problem – solution approach 492
processes, amorphous forms 508
proton transfer reaction 183
pseudoracemic crystalline phase 10
PVA hydrogels 270
PVP 231
PVP/VA64 233
PVPVA 234

q
Qmax value 289

r
Rac-modafinil, polymorphs of 294
racemic composition 136
racemic compound 136
racemization process 136
radius of gyration (R_g) 204
Raman and neutron scattering 396
Raman mapping 386
Raman microspectroscopy 386
Raman shift 363
Raman spectroscopy
– basic theory 362
– categories 361
– description 362
– equipment and procedures 364
– on-line 383
– molecular compounds analysis 365
Rayleigh scattering 363
regular conformations of chains 204
relaxation processes identification, dielectric spectra
– basics 312
– relaxation α 314
– secondary relaxations and excess wing 314
– structural relaxation α 312
reverse Monte Carlo type 290
D-ribose
– dielectric loss spectra 191
– relaxation times and static permittivity 191, 193
– selected kinetic curves 194
Rietveld refinement 292
ring molecules, conformational flexibility, *see* carbohydrates
ring-chain tautomerism 183, 185
rotational isomeric state model 166
rotationally disordered crystals 8
rotator phase 347
rubber like elasticity 250

s
S and R hydrogenosulfate, clopidogrel 148
scaffolds
– description 241
– design 241
– drug releasing requirements 269
– fabrication 268
– leaching techniques 275
– manufacturing techniques 275
– spinodal decomposition, *see* spinodal decomposition
– supercritical processing 274
– tissue engineering 268
Scherrer equation 6
Schoencke space groups 137
screw dislocation 89, 91, 96
second-order nonlinear optical imaging of chiral crystals (SONICC) 230
secondary relaxation processes 322
secondary relaxations and excess wing 314
semi-crystalline polymer 215, 225
– microstructure 225
semisolid dosages 242
shielding interaction 429
Shish-kebab organisation 208
Shish-kebab structure 209
sildenafil 328
simvastatin 402
slip 90
sol-gel transition 243, 261

solid crystalline imperfections, *see* crystal imperfections
solid dispersions 66, 67, 73
– dissolution behavior 67, 68
– supersaturation measurement 75
solid form 2
solid semi-crystalline polymer 165
solid state analysis 362
solid state NMR spectroscopy (SSNMR) 427, 502
– advantages 427
– basics 428
– cross polarization 432
– experimental approach 430
– internal interactions 430
– isotropic chemical shift 431
– uses 427
solid-state polymerisation 94
solubility
– amorphous compounds 64
– amorphous vs. crystalline celcoxib 61
– definition 58
– description 23
– enhancement ratio 66
– enhancing approaches
– – cocrystals 60
– – metastable polymorphs 60
– – milling 60
– – particle size reduction 59
– – salts 60
– indomethacine 23
– limit 24
– miscibility gap in liquid state 25
– supersaturation measurement 75
– van't Hoff type plots 61
solubility limit, small molecules in polymers 223
soluplus 234
solvent evaporation-based processing techniques
– film coating 482
– freeze drying 481
– spray drying 478
solvent volatility 275
sorbitol 48
spherulites 207, 208
spinodal decomposition
– organic-inorganic composite scaffolds 273
– ternary system 271
spontaneous enantioresolution phenomenon, *see* preferential enrichment
spray chilling/congealing 472
spray drying 480
spring and parachute effect 67
stacking faults 92
stereoregularity and configurations, linear polymers 202
Stokes-Einstein equations 333
stress induced phase transformation 99
structural relaxation α 312
structural relaxation, crystallization and 333
substitutional disorder 10
succinonitrile 400
sucrose crystals, dislocation dynamics simulations 99
supercooled liquids and glasses 397, 407
– fast secondary relaxation and caged dynamics,398
primary (α-) and secondary (β-) relaxations,397
vibrational density of states,399
supercooled pharmaceuticals, tautomerization kinetics 190
supercritical fluids (SCFs) 274
supersaturation measurement 75
surface etching 123
swelling, polymer gel 256
symmetry operation, restrictions 136

t

tablet, oral administration 57, 58
tautomeric pairs 184
tautomerization
– broadband dielectric spectroscopy
– – advantage 187
– – condensed materials 187
– description 183
– drug industry 183
– erythromycin 187
– supercooled pharmaceuticals 190
tautomers, frequency distribution 184
tazofelone 144, 145
telmisartan 327
terahertz frequencies, supercooled liquids and glasses
– fast secondary relaxation and caged dynamics 398
primary (α-) and secondary (β-) relaxations 398
vibrational density of states 399
terahertz spectroscopy
– crystallinity detection 410
– description 393
– exploration prior to THz-TDS
– – far-infrared spectroscopy 395
– Poley absorption,394
– Raman and neutron scattering 396
– naproxen study 413

terahertz spectroscopy (*contd.*)
– supercooled liquids and glasses 397
– primary (α-) and secondary (β-) relaxations 37, 46, 397
– time-domain 394
terahertz studies, disordered molecular solid
– disordered crystals 400, 402
– inorganic glasses 403
– polymers 402
theophylline, TEM images 105
thermal processing techniques
– dry powder coating 474
– hot melt extrusion (HME) and injection molding 474
– melt granulation 472
– melt-fusion method 471
– principles 470
– spray chilling/congealing 472
– thermal sintering/curing 473
thermal sintering/curing 473
thermally induced phase separation (TIPS) with solvent crystallization,270
thermodynamic approach, amorphous compounds, apparent solubility 22, 64
thermodynamics 320
– parameter 321
thermogravimetric analysis (TGA) 502
thermoreversible hydrogels 246
three nons of glass formers 35
time, temperature, transformation rate (T,T,T) diagram 16, 17
translational invariance 3
transmission electron microscopy
– characterization of defects 110
– applications, pharmaceutical samples analysis 107
– basics 105
– study of defects 112
triblock copolymer 233
triphenyl phosphite (TPP) 367
glacial phase 50
twin planes 91
twinning 92
twins 136
two-order-parameter (TOP) model 319

u

uric acid crystals 122

v

van't Hoff type plots 61
vibrational density of states (VDOS) 367, 399
vitrification by supercooling 28
vitrification 319, 407, 409
by supercooling 28
Vogel–Fulcher–Tamman (VFT) equation 36, 217

w

Williams, Landel, and Ferry (WLF) equation 38
Winter-Chambon criteria, gelation 264

x

X-ray diffraction topography
– applications 117
– basics 115
– characterization 116
– defects within crystals 118
X-ray powder diffraction 362

z

Zeeman interaction 429